Itamar Medical Ltd. reported that it received a purchase order of approximately $2 million for EndoPATTM, from AstraZeneca AB, a customer in the pharmaceutical industry, pursuant to an existing framework agreement. The purchase order was made in connection with clinical trials to be conducted by the said customer, also using the Company’s EndoPATTM. The Company expects to deliver the ordered products during 2020. The Company estimates that this order is not necessarily indicative of future levels of orders by said customer or of the EndoPAT product.